Sozinibercept clinical trials
Also written OPT-302.
How each study uses sozinibercept is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
5 studies that test it; most in 2021 (2)
| Year | Studies |
|---|---|
| 2015 | 1 |
| 2017 | 1 |
| 2018 | 1 |
| 2021 | 2 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 5 · Other 0
Opthea Limited (5)
Studies
Open first, then newest update. How each study uses sozinibercept is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 5
- OPT-302 With Aflibercept in Neovascular Age-related Macular Degeneration (nAMD)TerminatedPhase 3Opthea LimitedNCT04757636Written as 2.0 mg OPT-302
- OPT-302 With Ranibizumab in Neovascular Age-related Macular Degeneration (nAMD)TerminatedPhase 3Opthea LimitedNCT04757610Written as 2.0 mg OPT-302
- A Dose Ranging Study of OPT-302 With Aflibercept for Persistent Diabetic Macular EdemaCompletedPhase 1/2Opthea LimitedNCT03397264Written as OPT-302
- A Dose Ranging Study of OPT-302 With Ranibizumab in Neovascular (Wet) AMDCompletedPhase 2Opthea LimitedNCT03345082Written as OPT-302
- Study Evaluating the Safety, Pharmacokinetics and Pharmacodynamics of OPT-302 With or Without Lucentis™ in Patients With Wet AMDCompletedPhase 1Opthea LimitedNCT02543229Written as OPT-302
Codes
What other systems call sozinibercept · ClinicalTrials.gg INT016173
- UNII (FDA) C42QTP3IMXSOZINIBERCEPTOne source FDA
- NCI Thesaurus C188557SoziniberceptOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | C42QTP3IMX | SOZINIBERCEPT | One source FDA |
| NCI Thesaurus | C188557 | Sozinibercept | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.